(Q39444656)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

head and neck squamous cell carcinoma

16 January 2020

main subject

0 references

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christoph Springfeld

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

K Zaoui

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

S Bossow

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C Grossardt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

P K Plinkert

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

C von Kalle

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

G Ungerechts

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

11 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

181-191

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Engineered measles virus as a novel oncolytic therapy against prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Antibody-targeted cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

An oncolytic measles virus engineered to enter cells through the CD20 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

High-throughput detection and multiplex identification of cell contaminations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Therapeutic potential of oncolytic measles virus: promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Molecular therapy in head and neck oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

China approves world's first oncolytic virus therapy for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

Rescue and propagation of fully retargeted oncolytic measles viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

inferred from DOI database lookup

7 January 2021

based on heuristic

Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.75

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2011.75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22076043%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference